Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Cell-based therapy technology classifications and translational challenges
Guys Hospital, England.
Guys Hospital, England.
Guys Hospital, England.
Linköping University, Department of Physics, Chemistry and Biology, Biotechnology. Linköping University, Faculty of Science & Engineering. Guys Hospital, England.
2015 (English)In: Philosophical Transactions of the Royal Society of London. Biological Sciences, ISSN 0962-8436, E-ISSN 1471-2970, Vol. 370, no 1680, 20150017- p.Article, review/survey (Refereed) Published
Abstract [en]

Cell therapies offer the promise of treating and altering the course of diseases which cannot be addressed adequately by existing pharmaceuticals. Cell therapies are a diverse group across cell types and therapeutic indications and have been an active area of research for many years but are now strongly emerging through translation and towards successful commercial development and patient access. In this article, we present a description of a classification of cell therapies on the basis of their underlying technologies rather than the more commonly used classification by cell type because the regulatory path and manufacturing solutions are often similar within a technology area due to the nature of the methods used. We analyse the progress of new cell therapies towards clinical translation, examine how they are addressing the clinical, regulatory, manufacturing and reimbursement requirements, describe some of the remaining challenges and provide perspectives on how the field may progress for the future.

Place, publisher, year, edition, pages
ROYAL SOC , 2015. Vol. 370, no 1680, 20150017- p.
Keyword [en]
cell therapy; translation; regulation; clinical trial; manufacturing; reimbursement
National Category
Biological Sciences
Identifiers
URN: urn:nbn:se:liu:diva-122522DOI: 10.1098/rstb.2015.0017ISI: 000362719500012PubMedID: 26416686OAI: oai:DiVA.org:liu-122522DiVA: diva2:868042
Note

Funding Agencies|Innovate UK, an executive non-departmental public body of the UK Government

Available from: 2015-11-09 Created: 2015-11-06 Last updated: 2017-12-01

Open Access in DiVA

fulltext(803 kB)86 downloads
File information
File name FULLTEXT01.pdfFile size 803 kBChecksum SHA-512
8e64bba9dac323d0ad64de318449a2006a75094cb40c906f0528e73a256497a5dd2fcbb421d8b7a5932614f5a4ae066be28cde0240629d693f514627503d42d0
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Hyllner, Johan
By organisation
BiotechnologyFaculty of Science & Engineering
In the same journal
Philosophical Transactions of the Royal Society of London. Biological Sciences
Biological Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 86 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 146 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf